Annovis Bio Postpones Special Meeting to Nov 3, Drops Preferred Stock Increase from Proposal 1
ANVS is trading near its 52-week low of $1.04 (13% above the low).
Summary
The special meeting has been postponed to November 3, and Proposal 1 has been narrowed to only double authorized common stock to 140 million shares, dropping the preferred stock increase. A recent Delaware law change lowered the voting threshold and gave brokers discretionary voting authority.
Key Events · Corporate Governance and Compliance · ANVS
-
Special Meeting Postponed to November 3
The special meeting originally scheduled for October 14, 2026 has been rescheduled to November 3, 2026 at 10:00 a.m. ET, to allow stockholders to receive the supplement to the proxy statement.
-
Proposal 1 Narrowed to Common Stock Only
Proposal 1 now seeks only an increase in authorized common stock from 70 million to 140 million shares. The proposed increase in authorized preferred stock from 2 million to 10 million has been dropped.
-
Voting Threshold Lowered by Delaware Law Change
Due to an August 2026 amendment to the Delaware General Corporation Law (Section 242(d)(2)), Proposal 1 now requires approval by a majority of votes cast rather than a majority of shares outstanding. Abstentions and broker non-votes have no impact.
-
Brokers Gain Discretionary Voting Authority
Brokers now have discretionary authority to vote on Proposal 1 for street name holders who do not provide voting instructions, which could make approval easier to obtain.
Analysis · ANVS · Life Sciences
The special meeting has been pushed back from October 14 to November 3, 2026, and Proposal 1 has been materially narrowed to seek only a doubling of authorized common stock from 70 million to 140 million shares. The previously proposed increase in authorized preferred stock from 2 million to 10 million has been dropped. This change was driven by an August 2026 amendment to Delaware corporate law that lowered the voting threshold for listed common stock to a majority of votes cast, while preferred stock would still require a majority of shares outstanding. As a result, brokers now have discretionary authority to vote on Proposal 1, which could make approval easier to obtain. The company continues to face a going concern warning and a precarious cash position, and the additional authorized shares are needed to fund ongoing clinical trials and raise capital.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANVS was trading at $1.18 on NYSE in the Life Sciences sector, with a market capitalization of approximately $50.3M. The 52-week trading range was $1.04 to $5.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.